Actively Recruiting
Diffusion MRI in Heart Failure
Led by Massachusetts General Hospital · Updated on 2025-12-24
160
Participants Needed
1
Research Sites
600 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The development of symptomatic heart failure is frequently preceded by a pre-clinical period of structural remodeling in the heart. The remodeling process driving this transition, however, remains poorly understood. The investigators hypothesize that imaging the diffusion of water in the heart with MRI will allow its microstructure to be resolved. The investigators further hypothesize that the characterization of microstructural changes in the heart will help elucidate the pathogenesis of heart failure and the transition from a compensated to a decompensated state. Patients with recent myocardial infarcts and left ventricular hypertrophy, who are at risk for the development of heart failure, will be enrolled. The participants will undergo serial diffusion tensor MRI (DTI) imaging of the heart to characterize changes in myocardial microstructure over time.
CONDITIONS
Official Title
Diffusion MRI in Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adults with no history of hypertension, diabetes or heart disease
- Patients with ST Elevation MI within last 6-10 weeks who are angina free, and have been seen by a cardiologist since discharge
- Patients with episode of heart failure within last 12 months and left ventricular hypertrophy, documented by echocardiogram or MRI.
You will not qualify if you...
- Presence of metallic foreign bodies or objects
- Selected medical devices and implants
- Pacemakers, implantable defibrillators, life vests
- Coronary artery stent within last 6 weeks (unless the stent is a MRI-inert chromium-cobalt stent)
- Known untreated ventricular arrhythmia such as sustained ventricular tachycardia within last 12 months
- Atrial fibrillation that is not well rate controlled (heart rate greater than 125)
- Unstable angina within last 2 months not fully evaluated by a cardiologist
- Syncope within last 6 weeks
- Hemodynamic instability (Systolic blood pressure less than 100 or greater than 180)
- Decompensated heart failure (inability to lie flat and perform a breath-hold)
- Glomerular filtration rate (GFR) less than 60 for those receiving gadolinium
- Labile GFR that is not stable/similar on last 2 measurements (for those receiving gadolinium)
- Patients with GFR less than 20 or on any form of dialysis
- Infiltrative cardiomyopathy (amyloid, sarcoid, hemochromatosis)
- Recent surgery within the last 3 months
- Prior stroke with large residual deficit
- Presence of liver or respiratory failure
- Pregnancy and nursing mothers
- Claustrophobia
- Known seizure disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129
Actively Recruiting
Research Team
D
David E. Sosnovik, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here